PCA
RARE icon

Pallas Capital Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pallas Capital Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$287K Buy
+8,602
New +$214K 0.01% 750
2024
Q4 		– Sell
-10,904
Closed -$598K – 624
2024
Q3 		$598K Buy
+10,904
New +$555K 0.03% 318

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Pallas Capital Advisors's RARE Position: Q2 2026 in Review

Pallas Capital Advisors opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 8,602 shares worth $287K. The stake represents 0.01% of the portfolio and ranks #750 among its holdings. This is a return to the name: Pallas Capital Advisors previously reported a position in RARE as recently as Q3 2024.

Pallas Capital Advisors first reported a position in RARE in Q3 2024 and has held it in 2 quarters since. The position peaked at $598K in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Pallas Capital Advisors held 8,602 shares of Ultragenyx Pharmaceutical worth $287K as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new Pallas Capital Advisors position in Q2 2026.
  • Ultragenyx Pharmaceutical made up 0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #750 holding.
  • Pallas Capital Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and has held it in 2 quarters since.
  • Pallas Capital Advisors's Ultragenyx Pharmaceutical position peaked at $598K in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.